IP Library Granted Patent US 10,716,860
Granted Patent B2
US 10,716,860 · App. 15/811,040 · Granted Jul 21, 2020

Cochleates made with soy phosphatidylserine

Inventors: Raphael Mannino (Glen Gardner, NJ); Ruying Lu (New Providence, NJ)
Assignees: Matinas BioPharma Nanotechnologies, Inc.; Rutgers, The State University of New Jersey
A61K47/24A61K9/1274A61K9/1277A61K9/19A61K31/12A61K31/122A61K31/685A61K31/7036A61K31/7048A61K33/06A61K45/06A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,860
App. No.
15/811,040
Granted
Jul 21, 2020
Kind
B2
Abstract

Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.

Claims (22)

1. A cochleate comprising:

soy phosphatidylserine in an amount of about 40% to 70% by weight of a lipid component of the cochleate,

a multivalent cation,

a biological active, and

a bile salt, wherein the weight ratio of soy-based phospholipid to the bile salt is between 20:1 and 0.5:1.

2. The cochleate of claim 1 wherein the lipid component is a mixture composed of at least soy phosphatidylserine and phosphatidic acid.

3. The cochleate of claim 1 , wherein the cochleate is a crystal cochleate.

4. The cochleate of claim 1 , wherein the cochleate is a geode cochleate and further comprises an oil.

5. The cochleate of claim 1 , wherein the biological active is at least one member selected from the group consisting of a protein, a small peptide, a polynucleotide, an aminoglycoside, an antiviral agent, an anesthetic, an antibiotic, an antifungal agent, an anticancer agent, an immunosuppressant, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, a tranquilizer, a nutritional supplement, an herbal product, a vitamin and a vasodilatory agent.

6. The cochleate of claim 5 wherein the biological active is at least one member selected from the group consisting of an aminoglycoside, amphotericin B, acyclovir, adriamycin, cabamazepine, curcumin, melphalan, nifedipine, indomethacin, naproxen, estrogens, testosterones, steroids, phenytoin, ergotamines, cannabinoids, rapamycin, propanidid, propofol, alphadione, echinomycine, miconazole nitrate, teniposide, a taxane, paclitaxel, and taxotere.

7. The cochleate of claim 5 , wherein the biological active is an antibiotic.

8. The cochleate of claim 5 , wherein the biological active is an aminoglycoside.

9. The cochleate of claim 5 , wherein biological active is amphotericin B.

10. The cochleate of claim 5 , wherein biological active is a polynucleotide.

11. The cochleate of claim 1 , wherein the multivalent cation is Ca ++ , Zn ++ , Ba ++ , or Mg ++ .

12. The cochleate of claim 11 , wherein the multivalent cation is Ca ++ .

13. The cochleate of claim 12 , wherein the biological active is an antibiotic.

14. The cochleate of claim 12 , wherein the biological active is an aminoglycoside.

15. The cochleate of claim 12 , wherein biological active is amphotericin B.

16. The cochleate of claim 12 , wherein biological active is a polynucleotide.

17. The cochleate of claim 1 , wherein the weight ratio of soy-based phospholipid to the bile salts is between 10:1 and 3:1.

18. A method of treating a patient with a fungal or bacterial infection which comprises administering to the patient an effective anti-fungal or anti-bacterial amount of the cochleate of claim 1 , wherein the biological active comprises an anti-fungal or anti-bacterial agent.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2020
From: LU, RUYING
To: COORDINATED PROGRAM DEVELOPMENT, LLC
Reel/Frame 051791/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2020
From: MANNINO, RAPHAEL
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 051791/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2020
From: COORDINATED PROGRAM DEVELOPMENT, LLC
To: AQUARIUS BIOTECHNOLOGIES, INC.
Reel/Frame 051791/0905 →
CHANGE OF NAME Recorded Feb 12, 2020
From: AQUARIUS BIOTECHNOLOGIES, INC.
To: MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Reel/Frame 051900/0582 →
Continuity (4)
Continuation 14418392
Provisional Application 61835825 · Jun 17, 2013
Provisional Application 61677414 · Jul 30, 2012
Related Publication 20180185491A1 · Jul 5, 2018
Cited By (1)
US 12,409,227